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Abstract
Introduction: Hematology patients admitted to the ICU frequently experience respiratory failure and require
mechanical ventilation. Noninvasive mechanical ventilation (NIMV) may decrease the risk of intubation, but NIMV
failure poses its own risks.
Methods: To establish the impact of ventilatory management and NIMV failure on outcome, data from a
prospective, multicenter, observational study were analyzed. All hematology patients admitted to one of the 34
participating ICUs in a 17-month period were followed up. Data on demographics, diagnosis, severity, organ failure,
and supportive therapies were recorded. A logistic regression analysis was done to evaluate the risk factors
associated with death and NIVM failure.
Results: Of 450 patients, 300 required ventilatory support. A diagnosis of congestive heart failure and the initial use
of NIMV significantly improved survival, whereas APACHE II score, allogeneic transplantation, and NIMV failure
increased the risk of death. The risk factors associated with NIMV success were age, congestive heart failure, and
bacteremia. Patients with NIMV failure experienced a more severe respiratory impairment than did those electively
intubated.
Conclusions: NIMV improves the outcome of hematology patients with respiratory insufficiency, but NIMV failure
may have the opposite effect. A careful selection of patients with rapidly reversible causes of respiratory failure may
increase NIMV success.
Introduction
Patients admitted to the intensive care unit (ICU) with
hematologic malignancies are at high risk of death. Up to
15% of patients with acute leukemia [1] and 20% of those
undergoing bone marrow transplantation [2] may require
ICU admission. The presence of multiple organ failure in
this population has been associated with very high mor-
tality rates [3]. Acute respiratory failure is one of the
most prevalent organ failures [4], being the cause of ICU
admission in up to 40% [5]. Although mechanical ventila-
tion is the main supportive therapy for those with severe
gas-exchange impairment, the need for intubation has
been consistently described as one of the most adverse
factors in these patients [6,7].
Some reports suggest that the prognosis of these
patients has improved in recent years [8,9], although this
finding has not been constant among different series [5].
These improvements in the care of hematology patients
have led to broadening ICU admission policies [10]. The
different changes in the standard of care causing this
improvement include the application of noninvasive
mechanical ventilation (NIMV) in selected patients,
which could avoid the need for intubation and has been
shown to decrease mortality [11-13]. Conversely, failure
of noninvasive ventilation may lead to a delay in intuba-
tion and further impairment in organ failures. This has
been found in a randomized trial involving a mixed ICU
population [14]. Moreover, observational studies in
hematology patients have shown a similar result [6].
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Therefore, the type of respiratory support is one of the
main prognostic factors in hematology patients admitted
to the ICU. To clarify further the role of different ventila-
tory strategies in the outcome, we conducted an analysis
in a large cohort of these patients. Our objective was to
establish the risk of death associated with the initial ven-
tilatory approach (either invasive (IMV) or noninvasive)
and with the failure of noninvasive ventilation. Afterward,
we analyzed the variables related to an increased risk of
noninvasive ventilation failure.
Materials and methods
Study design
The EMEHU study was performed in 34 ICUs in Spain.
All the hematology patients admitted to one of the parti-
cipating ICUs from June 2007 to September 2008 were
prospectively included in a database. Data on demo-
graphics, underlying disease, main diagnoses at ICU
admission, previous and current treatments, comorbid-
ities, APACHE II severity score, supportive measure-
ments, infections, and the clinical course during the ICU
stay (including SOFA scores) were collected. Neutropenia
was defined as an absolute neutrophil count below 500/
mm3. Patients were followed up until hospital discharge
or death. The study was approved by each hospital’s
ethics committee, and informed consent for data collec-
tion was obtained from each patient’s next of kin.
All the patients included in the database who required
some form of positive-pressure ventilation were included
in the analysis. The cohort was split into two groups
according to their first type of positive-pressure ventila-
tion, either invasive or noninvasive. NIMV failure was
defined as the need for intubation after an NIMV trial,
irrespective of its duration. The main outcome variable
was ICU survival.
Data analysis
Data are expressed as mean (SD) or number (percentage),
as appropriate. Data from patients treated with IMV or
NIMV from the onset were compared by using T or c2
tests for continuous or categoric data, respectively. Uni-
variate comparisons between ICU survivors and nonsurvi-
vors were performed by using the Student t or c2 tests.
Variables with differences with a P value of 0.1 or less
were included in a logistic regression analysis. The good-
ness-of-fit was evaluated with the Hosmer-Lemeshow test.
Odds ratios (ORs) with their 95% confidence interval and
P values were estimated.
A similar method was used for the comparison between
patients with a successful NIMV trial and those with
NIMV failure: after univariate comparisons, variables
with a P of 0.1 or less were included in a logistic regres-
sion model. SOFA scores from patients from IMV,
NIMV success, and NIMV failure were compared by
using an ANOVA. Post hoc tests were done when appro-
priate with the Bonferroni correction. A P value equal to
0.05 or less was considered significant. All the statistical
calculations were done with SPSS 19 software (IBM,
Minneapolis, MN, USA).
Results
Impact of ventilation in survival
Of the 450 hematology patients admitted to the partici-
pating ICUs during the study period, 300 (66.7%)
required ventilatory support and were included in the
analysis. The main demographic and clinical data are
shown in Table 1. Overall mortality was 69%. Figure 1
shows the flow chart of the patients included in the
study.
First, we compared data from patients submitted to
IMV as the first option with those from patients who
were managed initially with NIMV. Patients in the IMV
group showed an increased severity (APACHE II score,
26.1 (8.4) versus 23.1 (7.8), P = 0.004), with no differ-
ences for age (54.3 (17) versus 53.4 (16.5) years; P = 0.91)
or sex (39.9% versus 34.4% females; P = 0.33). Both
groups showed a similar distribution of hematologic diag-
noses, rate of neutropenia, and type of hematopoietic
stem cell transplantation (HSCT, data not shown). At
ICU admission, patients assigned to IMV had higher
rates of shock (33.1% versus 19.1%; P = 0.007) and coma
(7.7% versus 0.8%; P = 0.004) and a lower incidence of
congestive heart failure (3% versus 10%; P = 0.014).
These results suggest that the most severely ill patients
were electively intubated and subject to IMV.
We then performed univariate comparisons between
ICU survivors and nonsurvivors and found that survivors
have lower APACHE II scores, lower incidence of shock,
and a higher incidence of congestive heart failure on
admission (Table 1). As expected, because of the previous
finding of increased severity in electively intubated
patients, significant differences were present between sur-
vivors and nonsurvivors in the type of respiratory support,
with lower mortality rates in patients receiving NIMV
(42.3%) than in those that were intubated from the onset
(72.2%) or after NIMV failure (79.7%). Of the 131 patients
managed initially with NIMV, 79 (60.3%) required intuba-
tion and invasive ventilation. No differences were found in
the day of onset of IMV (0.9 ± 1.5 versus 1.2 ± 1.6 days
for survivors and nonsurvivors, respectively; P = 0.33) or
NIMV (0.4 ± 0.7 versus 0.7 ± 1.2 days for survivors and
nonsurvivors, respectively; P = 0.14).
All the variables with a P value <0.1 were entered into
a logistic regression analysis. Goodness-of-fit was ade-
quate, with a P = 0.20 in the Hosmer-Lemeshow test.
The results of this analysis are shown in Table 2. We
found that APACHE II scores, allogeneic stem cell
transplantation, and NIVM failure were independent
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risk factors for increased ICU mortality in this popula-
tion. However, a diagnosis of congestive heart failure at
ICU admission and the initial use of NIMV were factors
that reduce the risk of NIMV failure. Adding an interac-
tion between initial ventilatory strategy and NIMV fail-
ure did not change the results (data not shown).
Overall, our data demonstrate the critical role of the
type of ventilatory support in the prognosis of hematol-
ogy patients.
Risk factors for NIVM failure
The previous logistic regression analysis demonstrates
that NIMV is associated with an improved outcome of
hematology patients requiring ventilatory support, but
the failure of NIVM increases significantly the risk of
death in this population (with an OR of 5.74), even
more than elective invasive ventilation (which results in
an OR of 3.13). Then we studied the differences
between patients with failure of NIMV and those who
do not require intubation. The duration of NIMV was
not different between groups (3.7 (4.5) and 3.3 (7.2)
days in NIMV success and failure groups, respectively;
P = 0.7), nor in-hospital stay before ICU admission
(13.9 [16.2] and 15.7 [20.2] days; P = 0.59). ICU stay
was shorter in patients with NIMV success (5.6 (4.8)
versus 14 (14.2) days; P < 0.001). Table 3 shows the dif-
ferences in univariate comparisons and the results of the
logistic regression. The NIMV-failure group patients
Table 1 Characteristics of the study sample, comparing intensive care unit survivors and nonsurvivors
Overall
n = 300
Survivors
n = 93
Nonsurvivors
n = 207
P value
Age, years (SD) 53.6 (16.7) 54.9 (14.6) 53.5 (17.5) 0.50
Women (%) 112 (37.5) 41 (36.6) 71 (63.4) 0.12
APACHE II (SD) 24.8 (8.3) 22.18 (7.4) 25.9 (8.3) 0.001
Main diagnosis (%) 0.79
Acute leukemia 127 (44.7) 37 (39.8) 90 (43.4)
Chronic leukemia 33 (11.6) 9 (9.7) 24 (11.6)
Hodgkin lymphoma 13 (4.3) 3 (3.2) 10 (4.8)
Non-Hodgkin lymphoma 76 (26.7) 26 (28) 50 (24.2)
Multiple myeloma 19 (6.3) 8 (8.6) 11 (5.3)
Myelodysplastic syndrome 10 (3.3) 2 (2.1) 8 (3.9)
Other 22 (7.3) 8 (8.6) 14 (6.8)
HSCT (%) 0.06
No 229 (76.3) 74 (79.6) 155 (74.9)
Autologous 26 (8.7) 11 (11.8) 15 (7.2)
Allogeneic 45 (15) 8 (8.6) 37 (17.9)
Neutropenia (%) 129 (15) 42 (32.6) 87 (67.4) 0.26
Diagnosis on ICU admission (%)
Shock 81 (27) 18 (19.4) 63 (30.4) 0.05
Infection (other than pneumonia) 100 (33) 35 (37.6) 65 (31.4) 0.29
Pneumonia 112 (37.3) 35 (37.6) 77 (37.2) 0.22
Other causes of respiratory failure 83 (27.6) 21 (22.6) 62 (30) 0.19
Congestive heart failure 20 (6.7) 8 (8.6) 12 (5.8) 0.01
Coma 14 (4.7) 3 (3.2) 11 (5.3) 0.51
Other 52 (17.3) 11 (11.8) 41 (19.8) 0.70
Bacteremia on admission (%) 95 (31.7) 31 (33.3) 64 (30.9) 0.68
Initial ventilatory support (%) 0.17
IMV 169 (56.3) 47 (50.5) 122 (58.9)
NIMV 131 (43.7) 46 (49.5) 85 (41.1)
NIMV failure 79 (26.3) 16 (17.2) 63 (30.4) <0.001
In-hospital days before ICU admission, days (SD) 14.7 (17.3) 15.2 (17.4) 13.4 (16.8) 0.42
Length of ICU stay, days (SD) 11.7 (13.2) 15.7 (16.6) 9.8 (11.0) <0.001
Values are given as number (%) or mean (SD). HSTC, hematopoietic stem cell transplantation; IMV, invasive mechanical ventilation; NIMV, noninvasive mechanical
ventilation.
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were younger and had a lower incidence of congestive
heart failure and bacteremia on admission. A trend
existed to a significant difference in the distribution of
hematologic diagnosis, and acute leukemia and myeloma
were less common in the NIMV failure group. In the
multivariate analysis, age, diagnosis of congestive heart
failure, or bacteremia on admission were risk factors
independently associated with a decreased risk of NIMV
failure. Again, the goodness-of-fit of the model was ade-
quate (Hosmer-Lemeshow; P = 0.31).
To test the hypothesis that NIMV failure could result
in additional systemic and respiratory derangement, we
compared the SOFA scores in the first 5 days after ICU
admission. Patients who were intubated as the first
option had higher SOFA scores at day 1. In case of
NIVM success, SOFA scores were lower at all time
points. However, NIVM failure was associated with
scores similar to the IMV group (Figure 2A). When
only the respiratory item in the SOFA scale was com-
pared, we found that, in the absence of differences at
day 1, the NIVM-failure group values were significantly
higher at later times (Figure 2B). No significant differ-
ences were found in other items of the score.
Discussion
The results reported here demonstrate the critical role of
the type of respiratory support in hematology patients. In
particular, the use of NIMV may have a dual effect: its
application results in a significant decrease in mortality,
but the failure after a NIMV trial increases the risk of
death. Additionally, we identified other factors related to
a poor outcome (severity, cause of respiratory derange-
ment) and NIMV failure. In contrast, a diagnosis of con-
gestive heart failure was related to improved outcomes.
Prognosis of hematology patients in the ICU
Hematologyl patients differ from other cancer patients
admitted to the ICU in their more-serious condition and
higher mortality rates, which may be as high as 40% to
50% [15]. Some of the prognostic factors found in our
study are consistent with previously published results.
Severity scores have been almost universally linked to
ICU outcome [16]. As the focus of our study was on
respiratory failure and its treatment in this population, all
the other significant variables were related to the cause of
lung injury or the type of respiratory support. The patient
selection may also explain the fact that other variables
commonly related to outcome, such as days before ICU
admission [17], were not significant in our model.
Impact of respiratory failure and its treatment
Increasing evidence suggests that the severity of organ
failure and persistence in time are of paramount impor-
tance for survival [11,18,19]. Specifically, the presence of
respiratory failure aggravates the prognosis and the
course of the disease in these patients, with an associated
mortality rate of about 50% [4]. This rate may increase
up to 75% to 90% when invasive mechanical ventilation is
needed [20]. Noninvasive mechanical ventilation has
emerged as an alternative with which to avoid intubation.
Along this line, several studies published in the last dec-
ade attribute to NIMV a protective effect, avoiding intu-
bation in up to half the cases, thus improving outcome
[11,21]. Therefore, NIMV has become the preferable
initial method of ventilation in this population. Our
results show that use of NIMV is related to a decreased
overall mortality in hematology patients.
450
Patients with 
hematological diseases 
admitted to the ICU
300
Patients required 
mechanical ventilation 
150
Patients did not 
required ventilatory 
support 
169
Patients received 
invasive ventilation 
131
Patients received
 non-invasive ventilation 
79
Patients required
late intubation 
52
Patients were not 
intubated
122 (72%)
Died in the ICU 
63 (80%)
Died in the ICU 
22 (42%)
Died in the ICU 
Figure 1 Study flow chart: patients included in the study,
according to the type of respiratory support received.
Table 2 Risk factors for death in the ICU, according to
logistic regression analysis
OR 95% confidence
interval
P
APACHE-II 1.06 1.02-1.10 0.002
Congestive heart failure on
admission
0.26 0.08-0.85 0.026
Shock on admission 1.69 0.86-3.33 0.131
NIMV as first ventilatory
approach
0.32 0.15-0.67 0.003
NIMV failure 5.74 2.40-13.73 <0.001
Allogeneic HSCT 6.78 1.78-25.85 0.005
HSCT, hematopoietic stem cell transplantation; OR, odds ratio; NIMV,
noninvasive mechanical ventilation.
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However, this form of ventilation may have some
drawbacks. The risk of NIVM failure in hematology
patients is high, with rates ranging from 50% to 70%
[13,19], in accord with our own result (60%). Previous
reports in a mixed ICU population showed an increase
in the risk of death after NIMV failure [22]. Similarly,
in a prospective, randomized study on the use of
NIVM to treat postextubation respiratory insufficiency,
failure of NIVM increased the risk of death [14].
Regarding our study population, the logistic regression
analysis shows that NIMV failure is an independent
predictor of death, with an OR >5. A similar result was
found in single-center observational studies [6,17], and
results from a large database of hematology patients
showed a higher, although nonsignificant, in-hospital
mortality in those intubated after an NIVM trial [12].
It has been hypothesized that NIMV failure may delay
the onset of optimal respiratory support in these
patients. The data that show worse scores in the SOFA
item measuring gas exchange support this point,
although the lack of standardized criteria for intuba-
tion, inherent in the observational nature of the study,
precludes any firm conclusion.
Our results highlight the relevance of NIMV failure as
an emerging concern when treating hematology patients
with respiratory insufficiency, especially because of the
increasing use of NIMV in hematology patients [7] and
the high failure rates reported.
Risk factors for NIMV failure
Several different factors lead to NIVM failure. An
increased severity of the disease, measured by using
scores such as SAPS II or by the number of organ fail-
ures, has been associated with increased intubation rates
[18,19]. However, we found no differences in the
APACHE II in our sample. The cause of the respiratory
failure also plays a key role in predicting the success of
NIMV. NIVM has been shown to be highly effective in
Table 3 Failure of noninvasive mechanical ventilation
Univariate comparison Logistic regression
NIV success
n = 52
NIV failure
n = 79
P value
(univariate)
OR 95% confidence interval P value
Age, years (SD) 58.1 (12.1) 50.4 (18.1) 0.004 0.958 0.932-0.985 0.002
Women (%) 22 (42) 23 (29) 0.13
APACHE II (SD) 22.3 (6.3) 23.7 (8.5) 0.37
Main diagnosis (%) 0.07
Acute leukemia 25 (48) 28 (35.4) 0.606 0.133-2.753 0.52
Chronic leukemia 4 (7.6) 14 (17.7) 3.482 0.531-22.834 0.19
Hodgkin lymphoma 2 (3.8) 6 (7.6) 2.495 0.241-25.835 0.44
Non-Hodgkin lymphoma 10 (19.2) 22 (27.8) 1.451 0.291-7.237 0.65
Multiple myeloma 6 (11.5) 2 (2.5) 0.245 0.028-2.170 0.21
Myelodysplastic syndrome 1 (1.9) 0 (0)
Other 0 (0) 1 (1.3)
HSCT (%) 0.60
No 39 (75) 62 (78.5)
Autologous 8 (15.4) 13 (16.4)
Allogeneic 5 (9.6) 4 (5.1)
Neutropenia (%) 24 (42) 33 (58) 0.54
Diagnosis on ICU admission (%)
Shock 12 (23) 13 (16.5) 0.37
Infection (other than pneumonia) 33 (63) 56 (70.9) 0.44
Pneumonia 20 (50) 38 (63.3) 0.28
Other causes of respiratory failure 12 (30.7) 26 (22.8) 0.22
Congestive heart failure 10 (19.2) 4 (5.1) 0.02 0.162 0.034-0.780 0.02
Coma 1 (1.9) 0 (0)
Other 3 (5.8) 8 (10.1) 0.38
Bacteremia on admission (%) 22 (42.3) 19 (24.1) 0.03 0.422 0.179-0.997 0.05
Univariate comparisons between patients with NIMV success and NIMV failure, and results of the logistic regression analysis. Values are given as number (%) or
mean (SD).
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cardiogenic pulmonary edema [23], consistent with pre-
vious studies [6] and our results. Conversely, its use in
cases of pneumonia, acute lung injury, or those without
an identified cause of respiratory failure is more contro-
versial [24]. The presence of acute lung injury as a risk
factor of NIVM failure in hematology patients was
recently confirmed in a large sample. However, no data
regarding congestive heart failure in this cohort were
reported [12]. Finally, bacteremia on admission was
another factor related to NIMV success [21]. It may be
argued that prompt and specific antibiotic treatment,
guided by microbiologic results, is strongly related to an
improved outcome, as shown by others [25].
Taken together, these results suggest that diseases that
may have a fast response to therapy, such as diuretics
and inotropes for cardiogenic pulmonary edema or
directed antibiotic therapy for a documented infection,
may benefit from NIMV. However, in other causes of
lung injury, NIMV may not support the ventilatory
function for a prolonged time, thus increasing the risk
of failure and intubation.
Conclusions
All of these results highlight the benefits and risks of
NIMV in critically ill hematology patients. Based on pre-
viously published data and our own results, it seems cri-
tical to select candidates carefully for NIMV among
those with rapidly reversible causes of respiratory failure
(that is, congestive heart failure). In other cases, the
delay in optimal respiratory support with IMV may
increase the risk of death.
Key messages
• Noninvasive mechanical ventilation improves survi-
val in hematology patients with acute respiratory
failure.
• However, failure of noninvasive ventilation
increases mortality, even more than does elective
invasive ventilation.
• Success of noninvasive ventilation is higher in con-
ditions with specific therapy, such as congestive
heart failure or documented bacteremia.
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